|Multi-Color Fluorescence Microscopy Application using Novel Brilliant Violet™ and Alexa Fluor® 594 Conjugated Monoclonal Antibodies|
Hong Zhang, Kelly Lundsten, Kevin Williams, Beibei Ding, Xiao Lin, Xifeng Wang, Jie Zhou, Dzung Nguyen, and John Ransom
Development of valuable new tools for the immunologist, to resolve multiple antigens simultaneously with fluorescence microscopy: Brilliant Violet 421™, Alexa Fluor® 488, Alexa Fluor® 594 and Alexa Fluor® 647 conjugated monoclonal antibodies.
|Discrimination of spectrally overlapping fluorochromes using Sony Corporation’s (SP6800) Spectral Analyzer|
Divekar AA, Lee MJ, Kakuta M, Nitta N, Furuki M, Yang XF and Ransom JT
SP6800, a novel spectral analyzer from Sony Corporation, uses an innovative optics system that collects all emitted light and eliminates the need for band pass filters. Our data show that the SP6800 can perform all the analysis similar to a traditional cytometer with the added feature of separating spectrally overlapping fluorophores.
|Comparison of Three Methods for the Evaluation of Cytokine Storm Risk in Early and Clinical Stage Biopharmaceutical Development|
Gary dos Santos and Emer Clarke
Objective: To identify an assay that can accurately predict the risk of CRS and CS associated with investigational biotherapeutics. A comparison of three methods were used: (a) immobilization of test antibody on plastic, (b) co-culture of PBMC's on HUVEC's and (c) pre-culture of PBMC's at high cell density.
|Stealth-Adapted Viruses and Viteria: Insights into Virus Construction, Replication and Potential Therapies|
W. John Martin
There is an increasing incidence of diseases with accompanying signs and symptoms of brain damage. These include neurological and psychiatric illnesses, childhood behavioral disorders, and such common conditions as chronic fatigue, Gulf War Syndrome, so-called “chronic Lyme disease”, and many cancers. Altogether, these diseases have an enormous social impact.
|Hypothesis of an Existence of a Reverse Pathway (Rp) which Passes Genetic Information from Polypeptide Antigens to Ig Genes in B-Lymphocytes|
Victor J. Alexander
Results of this research will bring new more effective treatment methods of many immune related diseases, including cancer.
|A mix-and-read cell-based assay for antibody screening against Epithelial Growth Factor Receptor |
Wayne P Bowen, David Onley, Paul Wylie, Diana Caracino and Tristan Cope
Here we present a sensitive robust, mix-and-read method for the screening of antibodies against cell surface proteins. With its simple operation, no-wash format, and high sensitivity, this new method is well-suited for high throughput antibody screening.
|Random Homozygous Gene Perturbation (RHGP) as a Tool for Target Discovery and Validation|
Wu-Bo Li and Michael Goldblatt
Random homozygous gene perturbation (RHGP) can identify and validate any host (cellular) gene target that directly causes a desired phenotype without requiring prior knowledge of the target. The central feature of RHGP is a unique lentiviral-based genetic element, known as a gene search vector (GSV) designed to interrogate the entire genome and identify target genes that cause the phenotype of interest.
|Metal Polymers, A Glue to Immobilise Proteins Onto Synthetic Surfaces|
Abernethy N, Chung E, Fontanelle BT, Gao Y, Jennins D, Koudijs MM, Lim D, Yang L, Ling T, Vukovic P, Wong A, Maeji, NJ
The main objective of this work was to develop a surface chemistry which maintains protein function and orientation per unit surface area, regardless of the surface used.
|Automated Solutions for Cellular Screening and Characterization of Therapeutic Antibodies for Antibody-Dependent Cellular Cytotoxicity Utility|
Brad Larson, Peter Banks , Nicolas Pierre, Stéphane Martinez, and Francois Degorce
Since the end of the 1990’s, the pharmaceutical industry has seen an increased interest in biologics, especially in the therapeutic areas of oncology and inflammation. Here we present the automation of two assays for the characterization and selection of potent antibody drug candidates. Both assays rely on HTRF® detection. The first assay quantifies the binding affinity of antibodies to their target antigen, on live cells.
|<< || 1 2 3 || >>|
|Showing Results 11 - 20 of 28||